Erythropoietin (EPO) Drugs Market Trends, Business Overview, Industry Growth and Forecast to 2028

The Erythropoietin (EPO) Drugs Market size is expected to grow at an annual average of 4% during 2022-2028. Erythropoietin (EPO)/hematopoietin is a glycoprotein hormone that induces red blood cell production in the bone marrow through red blood cell production. Erythropoietin drugs were developed to treat end-stage renal disease (ESRD) disease and anemia conditions resulting from dialysis procedures. Following the ESRD anemia condition, the EPO drug was approved for chemotherapy-induced anemia. After post-abbreviated new drug application (ANDA) approval and the high success rate of EPO application for chemotherapy-induced anemia, the original biopharmaceutical company turned its attention to another form of induced anemia, namely ART-induced anemia (among HIV patients). turned

The following segmentation are covered in this report:

By Application

• Hematology
• Kidney Disorder
• Cancer
• Others

By Product Type

• Epoetin-alfa
• Epoetin-beta
• Darbepoetin-alfa 
• Others

Company Profile

• Johnson & Johnson
• Amgen Inc.
• Roche, Hospira Inc.
• Biocon
• LG Life Sciences Ltd.
• Teva Pharmaceutical Industries Ltd.
• Intas Pharmaceuticals
• Ranbaxy Laboratories Ltd
• Celltrion, Inc.

Scope of the report

The research study analyses the Erythropoietin (EPO) Drugs Market industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent developments

• Market overview and growth analysis
• Import and export overview
• Volume analysis
• Current market trends and future outlook
• Market opportunistic and attractive investment segment

Geographic coverage

• North america market size and/or volume
• Latin america market size and/or volume
• Europe market size and/or volume
• Asia-pacific market size and/or volume
• Rest of the world market size and/or volume

Key Questions Answered by Erythropoietin (EPO) Drugs Market Report

• What was the Erythropoietin (EPO) Drugs Market size in 2021 and 2022; what are the estimated growth trends and market forecast (2022-2028)
• What will be the CAGR of Market during the forecast period (2022-2028)?
• Which segments (product type/applications/end-user) were most attractive for investments in 2021? How these segments are expected to grow during the forecast period (2022-2028).
• Which manufacturer/vendor/players in the Erythropoietin (EPO) Drugs Market was the market leader in 2021?
• Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.